MiniVax, Inc. and the University of Rochester have entered into an exclusive option agreement to develop a monoclonal antibody for the treatment of Pneumocystis pneumonia based on research conducted at the university. Pneumocystis pneumonia is an often fatal fungal respiratory infection that affects immunocompromised patients.
January 9, 2014 – Read more at BusinessWire
New Orleans BioInnovation Center granted funds to pilot diversity program in Life-Sciences Entrepreneurship Investment from JPMorgan Chase will help launch program in partnership with Xavier University of Louisiana NEW ORLEANS…
New technology revolutionizes DNA testing of sexual assault samples InnoGenomics SpermX™ delivers reliable results to solve sexual assault crimes NEW ORLEANS (March 28, 2023) – Addressing a long-term shortcoming in…
Local Biotech Company is Improving Clinical Care for Animals PetVet Dx celebrated recent expansion and future plans at a community event Friday NEW ORLEANS (March 31, 2023) Local biotech company…